The rationale for the combination of the monoclonal antibody NEO-201 with Immune Checkpoint Inhibitors (ICI)
DATE: 4/15/2024
Festival of Biologics 2024, April 15, 2024, San Diego, CA, San Diego Convention Center, Immunotherapy Keynote, Room 9, 11:30am PT
The rationale for the combination of the monoclonal antibody NEO-201 with Immune Checkpoint Inhibitors (ICI)
DATE: 12/14/2023
Dr. Philip M. Arlen gives presentation on recent NEO-201 clinical development at Biomarkers & Immuno US, 4th Annual Advances in Immuno-Oncology USA Congress, San Diego, CA, October 4, 2022
DATE: 10/4/2022
Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics, San Diego, March 9, 2022
DATE: 3/9/2022
Dr. Philip M. Arlen gives scientific presentation at Biomarkers UK: In-Person, November 8, 2021, Manchester, UK
DATE: 11/5/2021
Dr. Philip M Arlen, MD, President and CEO is Presenting the Following Talk entitled: “Developing mab Therapies From Tumor Neoantigens”, on October 28,2021
DATE: 10/28/2021
Dr Massimo Fantini, Director of Research is Presenting the following Talk entitled : “Stability Tests to Monitor the Shelf Life Of Monoclonal Antibodies Employed in Cancer Immunotherapy”, on October 26,2021
DATE: 10/26/2021
Dr. Philip M. Arlen gives scientific presentation at the 4th Annual Europe Neoantigen Summit 20th-22nd April 2021
DATE: 4/21/2021
Dr. Philip M. Arlen gives scientific presentation at the Festival of Biologics, World
Immunotherapy Congress, USA
DATE: 3/29/2021
Mechanisms of action of a neoantigen targeting antibody NEO 201
DATE: 3/3/2020
The Discovery and Development of Novel Monoclonal Antibody, NEO-201 Targeting a Novel Neoantigen
DATE: 3/10/2019